News & Events

Empower a Future Free of FTD with a Year-End Gift

For over 20 years, AFTD’s volunteers, supporters, and partners raised awareness, supported one another, educated healthcare professionals, advanced research, and advocated for a better tomorrow.   When you support AFTD’s mission,…

MORE

AFTD Research Team: A Year in Review

2024 has been a hopeful year for FTD Research, and it’s also been an exciting year for the AFTD research team. It isn’t easy to summarize all that’s been accomplished…

MORE

Article Lists Ways Researchers Can Involve People with Dementia in Identifying Research Priorities

A research article published in the Journal of the American Geriatrics Society discusses how researchers can better involve people living with FTD and other types of dementia in discussions to…

MORE

Perspectives in FTD Research Webinar: FTD Research 2024 – Where We’ve Come From and Where We’re Headed

The science of FTD is evolving at a rapid pace and it can be difficult to interpret the scientific advancements and how they may impact families facing an FTD diagnosis.…

MORE

AFTD Ambassador Advocates on Behalf of the Older Americans Act

AFTD Ambassador Judy Bearer advocated for the reauthorization of the Older Americans Act (OAA) in a December 8 opinion article published on the website Cleveland.com. Ms. Bearer, who has been…

MORE

Advancing Hope: AFTD Attends 2024 Society for Neuroscience Meeting

Dr. Nicole Bjorklund, AFTD Director of Research and Grants, and Dr. Kate Still, Research Outreach Manager, attended the Society for Neuroscience meeting in October to take in the latest research…

MORE

New York Software Company Awards AFTD Gift to Honor Employee’s Late Cousin

AFTD has been selected as one of three organizations to receive a gift from Mindex, a software-development company in Rochester, N.Y., in honor of the latter’s 30th anniversary charity initiative.…

MORE

Transposon Presents Results from Successful Phase 2 ALS/FTD Clinical Trial

Biotechnology company Transposon Therapeutics presented the results from its successful phase 2 clinical trial of its experimental medication for ALS/FTD at the 35th International Symposium on ALS/MND. The trial of…

MORE
SEE CALENDAR VIEW